Contributions
Abstract: P284
Type: Poster
Abstract Category: Clinical aspects of MS - Paediatric MS
Background: The incidence of acquired demyelinating syndromes (ADS) has not previously been estimated in Denmark in persons less than 18 years of age. Globally, few nationwide studies of the incidence of ADS have been published.
Aim: To determine the nationwide age- and sex-specific incidence of paediatric-onset ADS in Denmark from 1977 through 2015.
Methods: The nationwide Danish Multiple Sclerosis (MS) Registry provided cases of paediatric-onset MS. Furthermore, the National Patient Register was utilized to identify cases of paediatric-onset non-MS ADS of the central nervous system (International Classification of Diseases 8 or 10 in brackets): optic neuritis ("367.02", "367.01", "H46"), transverse myelitis ("323.02", "G37.3"), neuromyelitis optica ("341.00", "G36.0"), acute demyelinating encephalomyelitis ("323.03", "323.04", "G04.0"), or demyelinating disease of central nervous system ("G36" "G36.8", "G36.9", "G37.8", "G37.9"). Age- and sex-specific incidence rates including 95% confidence interval (95% CI) were estimated by the Poisson regression model.
Results: Based on 458 cases of MS and 690 cases of non-MS ADS with onset before 18 years of age, our study showed that the incidence rate per 100,000 person-years of MS was 0.58 (95% CI: 0.49-0.69) in males, and 1.42 (95% CI: 1.28-1.59) in females, and 0.99 (95% CI: 0.91-1.09) for both sexes. The female-to-male ratio was 2.32, and the median age at onset was 16 years with a range from 4-17 years. 143 cases of MS had onset before 15 years of age which resulted in an incidence rate of 0.52 (95% CI: 0.42-0.63) in females, and 0.24 (95% CI: 0.18-0.32) in males, and 0.38 (95% CI: 0.32-0.44) for both sexes. In contrast, the incidence rate of non-MS ADS was 1.25 (95% CI: 1.12-1.41) in males, and 1.75 (95% CI: 1.59-1.93) in females, and 1.50 (95% CI: 1.39-1.61) for both sexes. The female-to-male ratio was 1.33 with a median age at onset of 13 years and a range from 0-17 years.
Conclusion: The estimated age-specific incidence of paediatric-onset MS in Denmark is comparable with existing European epidemiological studies of paediatric-onset MS. Only 1/3 of the patients were 14 years and below at onset. This can be explained by a steadily increasing MS incidence through adolescence, particularly in females from 15 years of age and onwards. The incidence of non-MS ADS was 1.5 times higher than the rate of MS and almost twice as high as previously reported in the Netherlands.
Disclosure:
Magnus Boesen has received financial support for the current PhD project from Novartis, Teva, and Genzyme; received honoraria for lecturing from Novartis and support for congress participation from Teva.
Melinda Magyari has served on scientific advisory board for Biogen Idec and Novartis, Merck Serono, has received honoraria for lecturing from Biogen Idec, Merck Serono, Novartis, Genzyme, has received support for congress participation from Biogen Idec, Novartis, Genzyme, and Teva.
Nils Koch-Henriksen has received honoraria for lecturing and participation in advisory councils, travel expenses for attending congresses and meetings, and financial support for monitoring the Danish MS Treatment Register from Bayer-Schering, Merck-Serono, BiogenIdec, TEVA, Sanofi-Avensis, and Novartis.
Lau Caspar Thygesen has received honoraria for lecturing from Rigshospitalet (Copenhagen, Denmark), Statistics Denmark and Sanofi-Avensis.
Peter Born has nothing to disclose in relation to the content of this study
Peter Uldall has nothing to disclose in relation to the content of this study
Morten Blinkenberg has served on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Teva; received speaker honoraria from Biogen Idec, Merck-Serono, Bayer-Schering, Novartis, Teva, Roche and Sanofi-Aventis; received consulting honoraria from the Danish Multiple Sclerosis Society, Biogen Idec and Merck-Serono; has received funding for travel from Biogen Idec, Merck-Serono, Sanofi-Aventis, Genzyme and Solvay Pharma.
Abstract: P284
Type: Poster
Abstract Category: Clinical aspects of MS - Paediatric MS
Background: The incidence of acquired demyelinating syndromes (ADS) has not previously been estimated in Denmark in persons less than 18 years of age. Globally, few nationwide studies of the incidence of ADS have been published.
Aim: To determine the nationwide age- and sex-specific incidence of paediatric-onset ADS in Denmark from 1977 through 2015.
Methods: The nationwide Danish Multiple Sclerosis (MS) Registry provided cases of paediatric-onset MS. Furthermore, the National Patient Register was utilized to identify cases of paediatric-onset non-MS ADS of the central nervous system (International Classification of Diseases 8 or 10 in brackets): optic neuritis ("367.02", "367.01", "H46"), transverse myelitis ("323.02", "G37.3"), neuromyelitis optica ("341.00", "G36.0"), acute demyelinating encephalomyelitis ("323.03", "323.04", "G04.0"), or demyelinating disease of central nervous system ("G36" "G36.8", "G36.9", "G37.8", "G37.9"). Age- and sex-specific incidence rates including 95% confidence interval (95% CI) were estimated by the Poisson regression model.
Results: Based on 458 cases of MS and 690 cases of non-MS ADS with onset before 18 years of age, our study showed that the incidence rate per 100,000 person-years of MS was 0.58 (95% CI: 0.49-0.69) in males, and 1.42 (95% CI: 1.28-1.59) in females, and 0.99 (95% CI: 0.91-1.09) for both sexes. The female-to-male ratio was 2.32, and the median age at onset was 16 years with a range from 4-17 years. 143 cases of MS had onset before 15 years of age which resulted in an incidence rate of 0.52 (95% CI: 0.42-0.63) in females, and 0.24 (95% CI: 0.18-0.32) in males, and 0.38 (95% CI: 0.32-0.44) for both sexes. In contrast, the incidence rate of non-MS ADS was 1.25 (95% CI: 1.12-1.41) in males, and 1.75 (95% CI: 1.59-1.93) in females, and 1.50 (95% CI: 1.39-1.61) for both sexes. The female-to-male ratio was 1.33 with a median age at onset of 13 years and a range from 0-17 years.
Conclusion: The estimated age-specific incidence of paediatric-onset MS in Denmark is comparable with existing European epidemiological studies of paediatric-onset MS. Only 1/3 of the patients were 14 years and below at onset. This can be explained by a steadily increasing MS incidence through adolescence, particularly in females from 15 years of age and onwards. The incidence of non-MS ADS was 1.5 times higher than the rate of MS and almost twice as high as previously reported in the Netherlands.
Disclosure:
Magnus Boesen has received financial support for the current PhD project from Novartis, Teva, and Genzyme; received honoraria for lecturing from Novartis and support for congress participation from Teva.
Melinda Magyari has served on scientific advisory board for Biogen Idec and Novartis, Merck Serono, has received honoraria for lecturing from Biogen Idec, Merck Serono, Novartis, Genzyme, has received support for congress participation from Biogen Idec, Novartis, Genzyme, and Teva.
Nils Koch-Henriksen has received honoraria for lecturing and participation in advisory councils, travel expenses for attending congresses and meetings, and financial support for monitoring the Danish MS Treatment Register from Bayer-Schering, Merck-Serono, BiogenIdec, TEVA, Sanofi-Avensis, and Novartis.
Lau Caspar Thygesen has received honoraria for lecturing from Rigshospitalet (Copenhagen, Denmark), Statistics Denmark and Sanofi-Avensis.
Peter Born has nothing to disclose in relation to the content of this study
Peter Uldall has nothing to disclose in relation to the content of this study
Morten Blinkenberg has served on scientific advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Teva; received speaker honoraria from Biogen Idec, Merck-Serono, Bayer-Schering, Novartis, Teva, Roche and Sanofi-Aventis; received consulting honoraria from the Danish Multiple Sclerosis Society, Biogen Idec and Merck-Serono; has received funding for travel from Biogen Idec, Merck-Serono, Sanofi-Aventis, Genzyme and Solvay Pharma.